The Epidemiology and Outcome of Patients with Sepsis: Clear as Mud

  • R. S. Wax
  • D. C. Angus
Conference paper


Considerable resources have been expended in recent years towards the care of patients with sepsis. Our lack of impact on the survival of septic patients, despite many therapeutic trials, suggests that a review of disease characteristics may help guide future efforts with greater success. In this chapter, we will review the case definition, incidence and occurrence rates of sepsis. Some studies have suggested that the epidemiology of sepsis has changed over time, including changes in incidence, mortality and microbiological etiology. The outcome of patients with sepsis will be reviewed, including the role of prognostic indices. Finally, we will summarize data regarding the impact of therapy on patient outcome. Throughout these various aspects of discussion of sepsis, we will illustrate concerns that contribute to some confusion regarding understanding of the condition of sepsis.


Septic Shock Severe Sepsis Systemic Inflammatory Response Syndrome Case Definition Sepsis Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kieft H, Hoepelman AI, Zhou W et al (1993) The sepsis syndrome in a Dutch university hospital. Clinical observations. Arch Intern Med 153:2241–2247PubMedCrossRefGoogle Scholar
  2. 2.
    Reinhart K, Wiegand-Lohnert C, Grimminger F et al (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24:733–742PubMedCrossRefGoogle Scholar
  3. 3.
    Pittet D, Thievent B, Wenzel RP et al (1996) Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Am J Respir Crit Care Med 153:684–693PubMedGoogle Scholar
  4. 4.
    Bone RC, Balk RA, Cerra FB et al (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655PubMedCrossRefGoogle Scholar
  5. 5.
    Vincent JL (1997) Dear SIRS, I’m sorry to say that I don’t like you. Crit Care Med 25: 372–374PubMedCrossRefGoogle Scholar
  6. 6.
    Knaus WA, Sun X, Nystrom O et al (1992) Evaluation of definitions for sepsis. Chest 101: 1656–1662PubMedCrossRefGoogle Scholar
  7. 7.
    Center for Disease Control (1990) Increase in national hospital discharge survey rates for septicemia — United States, 1979–1987. Morbid Mortal Weekly Rep 39:31–34Google Scholar
  8. 8.
    Rangel-Frausto MS, Pittet D, Costigan M et al (1995) The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273:117–123PubMedCrossRefGoogle Scholar
  9. 9.
    Sands KE, Bates DW, Lanken PN et al (1997) Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA 278:234–240PubMedCrossRefGoogle Scholar
  10. 10.
    Brun-Buisson C, Doyon F, Carlet J et al (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. JAMA 274:968–974PubMedCrossRefGoogle Scholar
  11. 11.
    Salvo I, de Cian W, Musicco M et al (1995) The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 21[Suppl]2:5244-S249CrossRefGoogle Scholar
  12. 12.
    Angus DC, Dougnac A, Hernandez G et al (1996) Sepsis and SIRS: Are we any nearer to consensus? Intensive Care Med 22:273Google Scholar
  13. 13.
    Quartin AA, Schein RM, Kett DH et al (1997) Magnitude and duration of the effect of sepsis on survival. JAMA 277:1058–1063PubMedCrossRefGoogle Scholar
  14. 14.
    Friedman G, Silva E, Vincent JL (1998) Has the mortality of septic shock changed with time. Crit Care Med 26:2078–2086PubMedCrossRefGoogle Scholar
  15. 15.
    Cohen NH (1998) Reduced mortality from septic shock — lessons for the future. Crit Care Med 26:1956–1958PubMedCrossRefGoogle Scholar
  16. 16.
    Perl TM, Dvorak L, Hwang T et al (1995) Long-term survival and function after suspected gram-negative sepsis. JAMA 274:338–345PubMedCrossRefGoogle Scholar
  17. 17.
    Lundberg JS, Perl TM, Wiblin T et al (1998) Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med 26:1020–1024PubMedCrossRefGoogle Scholar
  18. 18.
    Le Gall JR, Lemeshow S, Leleu G et al (1995) Customized probability models for early severe sepsis in adult intensive care patients. Intensive Care Unit Scoring Group. JAMA 273: 644–650PubMedCrossRefGoogle Scholar
  19. 19.
    Knaus WA, Harrell FEJ, Labrecque JF et al (1996) Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-lra Phase III Sepsis Syndrome Study Group. Crit Care Med 24:46–56Google Scholar
  20. 20.
    Calandra T, Gerain J, Heumann D et al (1991) High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. The Swiss-Dutch J5 Immunoglobulin Study Group. Am J Med 91:23–29PubMedCrossRefGoogle Scholar
  21. 21.
    Damas P, Reuter A, Gysen P et al (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975–978PubMedCrossRefGoogle Scholar
  22. 22.
    Marks JD, Marks CB, Luce JM et al (1990) Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis 141:94–97PubMedGoogle Scholar
  23. 23.
    de Groote MA, Martin MA, Densen P et al (1989) Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs placebo. JAMA 262:249–251PubMedCrossRefGoogle Scholar
  24. 24.
    Debets JM, Kampmeijer R, van der Linden MP et al (1989) Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 17:489–494PubMedCrossRefGoogle Scholar
  25. 25.
    Calandra T, Baumgartner JD, Grau GE et al (1990) Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 161:982–987PubMedCrossRefGoogle Scholar
  26. 26.
    Pinsky MR, Vincent JL, Deviere J et al (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103:565–575PubMedCrossRefGoogle Scholar
  27. 27.
    Mira JP, Cariou A, Grall F et al (1999) Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality. A multicenter study. JAMA 282: 561–568PubMedCrossRefGoogle Scholar
  28. 28.
    Kumar A, Short J, Parrillo JE (1999) Genetic factors in septic shock. JAMA 282:579–581PubMedCrossRefGoogle Scholar
  29. 29.
    Manie TJ (1998) Community-acquired pneumonia: epidemiology, etiology, treatment. Infect Dis Clin North Am 12:723–740CrossRefGoogle Scholar
  30. 30.
    Linde-Zwirble WT, Angus DC, Carcillo J et al (1999) Age-specific incidence and outcome of sepsis in the US. Crit Care Med 27:A33CrossRefGoogle Scholar
  31. 31.
    Opal SM, Cohen J (1999) Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 27:1608–1616PubMedCrossRefGoogle Scholar
  32. 32.
    Mccloskey RV, Straube RC, Sanders C et al (1994) Treatment of septic shock with human monoclonal antibody HA-lA. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 121:1–5PubMedGoogle Scholar
  33. 33.
    Ziegler EJ, Fisher CJ Jr, Sprung CL et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-lA human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436PubMedCrossRefGoogle Scholar
  34. 34.
    Greenman RL, Schein RM, Martin MA et al (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097–1102PubMedCrossRefGoogle Scholar
  35. 35.
    Bone RC, Balk RA, Fein AM et al (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23:994–1006PubMedCrossRefGoogle Scholar
  36. 36.
    Exley AR, Cohen J, Buurman W et al (1990) Monoclonal antibody to TNF in severe septic shock. Lancet 335:1275–1277PubMedCrossRefGoogle Scholar
  37. 37.
    Fisher CJJ, Opal SM, Dhainaut JF et al (1993) Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 21:318–327PubMedCrossRefGoogle Scholar
  38. 38.
    Fisher CJJ, Agosti JM, Opal SM et al (1996) Treatment of septic shock with the tumor necrosis factor receptor:fc fusion protein. N Engl J Med 334:1697–1702PubMedCrossRefGoogle Scholar
  39. 39.
    Cohen J, Carlet J (1996) Intersept: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24:1431–1440PubMedCrossRefGoogle Scholar
  40. 40.
    Dhainaut JF, Vincent JL, Richard C et al (1995) CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 23:1461–1469PubMedCrossRefGoogle Scholar
  41. 41.
    Abraham E, Glauser MP, Butler T et al (1997) p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45–2081 Study Group. JAMA 2 77:15 31–1 53 8Google Scholar
  42. 42.
    Abraham E, Wunderink RG, Silverman H et al (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273:934–941PubMedCrossRefGoogle Scholar
  43. 43.
    Bernard GR, Wheeler AP, Russell JA et al (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336:912–918PubMedCrossRefGoogle Scholar
  44. 44.
    Haupt MT, Jastremski MS, Clemmer TP et al (1991) Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit Care Med 19:1339–1347PubMedCrossRefGoogle Scholar
  45. 45.
    Natanson C, Esposito CJ, Banks SM (1998) The sirens’ songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 26:1927–1931PubMedCrossRefGoogle Scholar
  46. 46.
    Bone RC (1996) Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125:680–687PubMedGoogle Scholar
  47. 47.
    Vincent JL (1998) Search for effective immunomodulating strategies against sepsis. Lancet 351:922–923PubMedGoogle Scholar
  48. 48.
    Bone RC (1996) Why sepsis trials fail. JAMA 276:565–566PubMedCrossRefGoogle Scholar
  49. 49.
    Inman KJ, Martin CM, Sibbald WJ (1992) Design and conduct of clinical trials in critical care. J Crit Care 7:118–128CrossRefGoogle Scholar
  50. 50.
    Bone RC (1995) Sepsis and controlled clinical trials: the odyssey continues. Crit Care Med 23:1313–1315PubMedCrossRefGoogle Scholar
  51. 51.
    Abraham E (1999) Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 25:556–566PubMedCrossRefGoogle Scholar
  52. 52.
    Schulman KA, Glick HA, Rubin H et al (1991) Cost-effectiveness of HA-1 A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent. JAMA 266:3466–3471PubMedCrossRefGoogle Scholar
  53. 53.
    Linden PK, Angus DC, Chelluri L et al (1995) The influence of clinical study design on costeffectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody. J Crit Care 10:154–164PubMedCrossRefGoogle Scholar
  54. 54.
    Bollaert PE, Charpentier C, Levy B et al (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26:645–650PubMedCrossRefGoogle Scholar
  55. 55.
    Briegel J, Forst H, Haller M et al (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 27: 723–732PubMedCrossRefGoogle Scholar
  56. 56.
    Chalfin DB, Cohen IL, Lambrinos J (1995) The economics and cost-effectiveness of critical care medicine. Intensive Care Med 21:952–961PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • R. S. Wax
  • D. C. Angus

There are no affiliations available

Personalised recommendations